BR112019003950A2 - identificação de mutações em variantes de canalopsina que têm sensibilidade à luz melhorada e métodos de uso da mesma - Google Patents
identificação de mutações em variantes de canalopsina que têm sensibilidade à luz melhorada e métodos de uso da mesmaInfo
- Publication number
- BR112019003950A2 BR112019003950A2 BR112019003950A BR112019003950A BR112019003950A2 BR 112019003950 A2 BR112019003950 A2 BR 112019003950A2 BR 112019003950 A BR112019003950 A BR 112019003950A BR 112019003950 A BR112019003950 A BR 112019003950A BR 112019003950 A2 BR112019003950 A2 BR 112019003950A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- channelopsin
- mutations
- variants
- identification
- Prior art date
Links
- 206010034960 Photophobia Diseases 0.000 title 1
- 208000013469 light sensitivity Diseases 0.000 title 1
- 230000035772 mutation Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 230000001771 impaired effect Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000016732 phototransduction Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/405—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Neurology (AREA)
Abstract
a invenção refere-se a composições e kits incluindo pelo menos um ácido nucleico ou molécula de polipeptídeo que codifica uma proteína cochop mutante. os métodos da invenção incluem administrar uma composição que compreende um cochop mutante a um sujeito para preservar, melhorar ou restaurar a fototransdução. preferencialmente, as composições e métodos da invenção são fornecidos a um sujeito que tem visão prejudicada, assim restaurando a visão para níveis normais.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662380871P | 2016-08-29 | 2016-08-29 | |
PCT/US2017/049158 WO2018044912A1 (en) | 2016-08-29 | 2017-08-29 | Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019003950A2 true BR112019003950A2 (pt) | 2019-06-25 |
Family
ID=59859616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019003950A BR112019003950A2 (pt) | 2016-08-29 | 2017-08-29 | identificação de mutações em variantes de canalopsina que têm sensibilidade à luz melhorada e métodos de uso da mesma |
Country Status (14)
Country | Link |
---|---|
US (2) | US11041004B2 (pt) |
EP (1) | EP3504227A1 (pt) |
JP (1) | JP7116884B2 (pt) |
KR (2) | KR20230169427A (pt) |
CN (1) | CN110023327B (pt) |
AU (3) | AU2017319306B2 (pt) |
BR (1) | BR112019003950A2 (pt) |
CA (1) | CA3034887A1 (pt) |
IL (2) | IL310142A (pt) |
MX (1) | MX2019002321A (pt) |
MY (1) | MY197491A (pt) |
RU (1) | RU2019109021A (pt) |
SG (2) | SG10202102061SA (pt) |
WO (1) | WO2018044912A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3504227A1 (en) | 2016-08-29 | 2019-07-03 | Wayne State University | Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof |
CN113173984B (zh) * | 2021-04-12 | 2022-08-30 | 中眸医疗科技(武汉)有限公司 | 一种新型光敏感通道蛋白vr1.0在制备视网膜感光细胞退行性疾病药物中的应用 |
CN117858894A (zh) * | 2021-12-20 | 2024-04-09 | 健达九州(北京)生物科技有限公司 | 用光敏性gq偶联神经视蛋白(视蛋白5)的光遗传学视觉恢复 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
WO1992008796A1 (en) | 1990-11-13 | 1992-05-29 | Immunex Corporation | Bifunctional selectable fusion genes |
WO1994028143A1 (en) | 1993-05-21 | 1994-12-08 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
CA2183667A1 (en) | 1994-02-22 | 1995-08-24 | Wayne A. Marasco | Nucleic acid delivery system, method of synthesis and uses thereof |
EP2465925A1 (en) | 2005-07-22 | 2012-06-20 | The Board Of Trustees Of The Leland | Light-activated cation channel and uses thereof |
CN101484005A (zh) | 2006-05-04 | 2009-07-15 | 韦恩州立大学 | 通过向体内递送视紫红质核酸恢复视觉响应 |
US20100008170A1 (en) | 2006-06-27 | 2010-01-14 | Shinya Sato | Semiconductor tester and testing method of semiconductor memory |
ES2801679T3 (es) | 2011-11-12 | 2021-01-12 | Massachusetts Inst Technology | Canalrodopsinas para el control óptico de células |
EP2822964B1 (en) | 2012-03-05 | 2018-08-22 | Wayne State University | Identification of channelrhodopsin-2 (chop2) mutations and methods of use |
EP2968476B1 (en) * | 2013-03-14 | 2021-05-05 | Wayne State University | A plasmin for use in enhancing delivery of therapeutic compounds to the eyes or for improving vision |
WO2015167639A1 (en) | 2014-02-07 | 2015-11-05 | Massachusetts Institute Of Technology | Blue light-activated ion channel molecules and uses thereof |
US10590181B2 (en) | 2014-04-18 | 2020-03-17 | Massachusetts Institute Of Technology | Mutant channelrhodopsins with altered ion selectivity |
US11324824B2 (en) * | 2016-06-03 | 2022-05-10 | Massachusetts Institute Of Technology | Somatic opsins for single cell resolution optogenetics |
EP3504227A1 (en) | 2016-08-29 | 2019-07-03 | Wayne State University | Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof |
-
2017
- 2017-08-29 EP EP17767952.9A patent/EP3504227A1/en active Pending
- 2017-08-29 SG SG10202102061SA patent/SG10202102061SA/en unknown
- 2017-08-29 CA CA3034887A patent/CA3034887A1/en active Pending
- 2017-08-29 IL IL310142A patent/IL310142A/en unknown
- 2017-08-29 JP JP2019531572A patent/JP7116884B2/ja active Active
- 2017-08-29 KR KR1020237041296A patent/KR20230169427A/ko active Search and Examination
- 2017-08-29 KR KR1020197008895A patent/KR102609571B1/ko active IP Right Grant
- 2017-08-29 MY MYPI2019001044A patent/MY197491A/en unknown
- 2017-08-29 US US16/328,916 patent/US11041004B2/en active Active
- 2017-08-29 RU RU2019109021A patent/RU2019109021A/ru unknown
- 2017-08-29 CN CN201780060143.3A patent/CN110023327B/zh active Active
- 2017-08-29 SG SG11201901697QA patent/SG11201901697QA/en unknown
- 2017-08-29 IL IL265010A patent/IL265010B1/en unknown
- 2017-08-29 AU AU2017319306A patent/AU2017319306B2/en active Active
- 2017-08-29 BR BR112019003950A patent/BR112019003950A2/pt unknown
- 2017-08-29 WO PCT/US2017/049158 patent/WO2018044912A1/en unknown
- 2017-08-29 MX MX2019002321A patent/MX2019002321A/es unknown
-
2021
- 2021-05-19 US US17/324,501 patent/US20220089660A1/en active Pending
-
2022
- 2022-02-25 AU AU2022201291A patent/AU2022201291B2/en active Active
-
2024
- 2024-01-02 AU AU2024200016A patent/AU2024200016A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2022201291B2 (en) | 2023-10-05 |
IL310142A (en) | 2024-03-01 |
MY197491A (en) | 2023-06-19 |
KR20230169427A (ko) | 2023-12-15 |
MX2019002321A (es) | 2019-10-21 |
US20220089660A1 (en) | 2022-03-24 |
KR20190075906A (ko) | 2019-07-01 |
JP2019528781A (ja) | 2019-10-17 |
AU2017319306B2 (en) | 2021-12-02 |
CN110023327B (zh) | 2024-02-27 |
CA3034887A1 (en) | 2018-03-08 |
SG11201901697QA (en) | 2019-03-28 |
KR102609571B1 (ko) | 2023-12-01 |
AU2024200016A1 (en) | 2024-01-25 |
IL265010B1 (en) | 2024-02-01 |
AU2022201291A1 (en) | 2022-03-17 |
WO2018044912A1 (en) | 2018-03-08 |
JP7116884B2 (ja) | 2022-08-12 |
EP3504227A1 (en) | 2019-07-03 |
SG10202102061SA (en) | 2021-04-29 |
IL265010A (pt) | 2019-04-30 |
RU2019109021A (ru) | 2020-09-29 |
RU2019109021A3 (pt) | 2021-02-02 |
AU2017319306A1 (en) | 2019-04-11 |
CN110023327A (zh) | 2019-07-16 |
US20190241628A1 (en) | 2019-08-08 |
US11041004B2 (en) | 2021-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018072946A2 (pt) | proteínas de fusão a gdf15 e usos das mesmas | |
BR112018008766A2 (pt) | variantes, composições e métodos e utilizações do fator viii reduzido cpg para o tratamento de transtornos hemostásicos | |
MX2014010664A (es) | Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso. | |
BR112017015567A2 (pt) | proteína gl de citomegalovírus recombinante ou fragmento de formação de complexo da mesma, complexo de citomegalovírus, ácido nucleico isolado, célula hospedeira, e, composição imunogênica | |
CO2018003863A2 (es) | Anticuerpos anti-vegf | |
AR127361A2 (es) | Composición farmacéutica de partículas de lipoplejos y arn, composición acuosa y método de preparación | |
BR112021005769A2 (pt) | proteínas de ligação a dll3 e métodos de uso | |
BR112017026523A2 (pt) | vetor recombinante, adenovírus recombinante, composição, uso de um vetor recombinante, de um adenovírus recombinante ou de uma composição, método para induzir uma resposta imune em um indivíduo, e, polinucleotídeo isolado. | |
BR112019011860A2 (pt) | proteína de fusão insulina-fc, sequência de ácido nucleico recombinante que codifica a mesma, vetor, célula eucariótica modificada, kit e método para tratar ou prevenir o diabetes autoimune | |
BR112016014810A2 (pt) | Antagonistas de fcrn e métodos de uso | |
BR112017020986A2 (pt) | proteínas de ligação recombinantes e seu uso | |
BR112018001572A2 (pt) | método para induzir uma resposta imune, antígeno, adenovírus, uso de um antígeno e de um adenovírus, e, polinucleotídeo. | |
FR3041505B1 (fr) | Composition acide comprenant au moins une phycocyanine stable a ph acide | |
BR112019003950A2 (pt) | identificação de mutações em variantes de canalopsina que têm sensibilidade à luz melhorada e métodos de uso da mesma | |
PE20170771A1 (es) | Composiciones y metodos de uso para tratar trastornos metabolicos | |
BR112015020235A2 (pt) | fragmento biologicamente ativo de proteína csf-1 ou um seu homólogo, ácido nucléico, proteína de fusão, ácido nucléico isolado, vetor, célula hospedeira, método de realização da proteína de fusão do primeiro aspeto da invenção, composição, utilização de uma proteína de fusão, método de tratamento para um indivíduo sofrendo de cancro do fígado e que irá ser submetido a cirurgia, método de tratamento para um indivíduo que irá ser submetido a cirurgia de transplante de fígado, e, kit | |
BR112017019625A2 (pt) | udp-glicosiltransferases | |
BR112017025728A2 (pt) | fragmentos mutantes da proteína ras | |
BR112022012230A2 (pt) | Variantes de progranulina | |
EA201892554A1 (ru) | Мутант cd200 и его применения | |
BR112018008840A2 (pt) | anticorpos de domínio único direcionados contra antígenos intracelulares | |
BR112019000215A2 (pt) | depleção de cistina mediada por enzima humana | |
BR112018073674A2 (pt) | polipeptídeo glicosilado, proteína glicosilada, uso de um polipeptídeo glicosilado, composição, polinucleotídeo isolado, vetor, e célula hospedeira | |
BR112022008201A2 (pt) | Degradação de proteínas de superfície usando agente de ligação biespecífico | |
EA201892254A1 (ru) | Экстракт табачного листа и его применение для лечения табачной зависимости |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |